Published in final edited form as:

Org Lett. 2012 February 17; 14(4): 968–971. doi:10.1021/ol203088g.

Halocarbocyclization Entry into the Oxabicyclo[4.3.1]decyl Exomethylene- δ -Lactone Cores of Linearifolin and Zaluzanin A - Exploiting Combinatorial Catalysis

Sandeep K. Ginotra, Jacob A. Friest, and David B. Berkowitz*

Department of Chemistry, University of Nebraska, Lincoln, NE 68588-0304

Abstract

A streamlined entry into the sesquiterpene lactones (SQL) cores of linearifolin and zaluzanin A is described. Stereochemistry is controlled through transformations uncovered by ISES (In-Situ-Enzymatic-Screening). Absolute stereochemistry derives from kinetic resolution of 5-benzoyloxypentene-1,2-oxide, utilizing a β -pinene-derived-Co(III)-salen. Relative stereochemistry (1,3-cis-fusion) is set via formal halometalation/carbocyclization, mediated by $[\text{Rh}(\text{O}_2\text{CC}_3\text{F}_7)_2]_2/\text{LiBr}$. Subsequent ring-closing metathesis (RCM-Grubbs II) yields the title exomethylene- δ -lactone SQL-cores. In complementary fashion, RCM with Grubbs-I catalyst provides the oxabicyclo[3.3.1]nonyl-core of xerophilusin R and zinagrandinolide.

ISES (In Situ Enzymatic Screening)-assisted catalyst development has led to the (i) discovery of the first asymmetric Ni(0)-mediated allylic amination chemistry,¹ (ii) new halometalation/carbocyclization transformations² and (iii) the identification of novel chiral salen ligands for asymmetric catalysis.³ This Letter describes the deployment of the latter two methods for stereocontrolled entry into bicyclic terpenoid natural product (NP) cores bearing a reactive exomethylene δ -lactone functionality.

This functional group has been linked to NF κ B-inhibition via active site cysteine capture, leading Merfort to propose a QSAR model for NF κ B inhibition/anti-cancer activity in such sesquiterpene lactones (SQLs).⁴ Against this medicinal chemistry backdrop there has been vigorous synthetic activity in the exomethylene SQL area,⁵ including approaches that permit core synthesis⁶ and chain extension.⁷ While a number of routes focus on end game methylenation,⁸ we favored a convergent strategy in which a formal halometalation/carbocyclization would at once close the lactone, control ring fusion geometry, and set in place the reactive, conjugated exomethylene moiety.² This approach has an added benefit for chemical biology; as the resultant β -bromo- α , β -unsaturated carbonyl system should be advantageous for library generation.⁹

dbb@unlserve.unl.edu.

Supporting Information Available Experimental details, characterization, NMR spectra and HPLC traces.

Targeted herein are the cores of SQLs carrying this functionality within a bridged oxabicyclo[4.3.1]decyl framework, as in linearifolin angelate¹⁰ (Fig. 1; from *H. linearifolium*, related to fastigilin A, a potent anti-neoplastic agent)¹¹ and zaluzanin A (muscle relaxant).¹²

Interestingly, these two terpenoid lactone cores have opposite handedness, therefore efficient hydrolytic kinetic resolution (HKR)^{3, 13} should allow for assembly of both cores from a common racemic epoxide building block precursor (Fig. 2), one from the diol product (as the cyclic sulfate), the other from the remaining epoxide. Such a convergent sequence would both allow for the efficient assembly of the exomethylene δ -lactone and set the cis-1,3-fusion stereochemistry in the key halometalation-carbocyclization step, a transformation for which both Rh-perfluorocarboxylate and Pd(II) catalysts have been uncovered recently in our lab.^{2,14}

Toward this end, an improved ISES screen [Fig. 3-new KRED (ketoreductase) enzymes¹⁵] identified salen **4a** catalyst, assembled from the β -pinene-derived diamine and α -hydroxy- β -naphthaldehyde, in its Co(III)-OAc form as a generally (*S*)-selective catalyst for terminal epoxides. This KRED assay has advantages over the previously reported hexene oxide screen;^{3a} as the two reporting enzymes show opposite enantioselectivities (see Supporting Information) and both are readily available. For the synthesis at hand, efficient HKR of an *O*-protected 5-hydroxy-1,2-pentene oxide was desired. Accordingly, a series of such potential building blocks were screened for HKR with Co(III)-**4a**-OAc. As can be seen (Table 1), this catalyst is generally (*S*)-selective for substrates bearing arylmethyl ether protecting groups.

In the event, when racemic **9** was treated with Co(III)-**4a**-OAc, on a 13 g scale, both antipodal building blocks, (*R*)-epoxide **9b** and (*S*)-diol **12** were obtained in high ee (Scheme 1) attesting to the potential^{3a} of this new chiral salen in asymmetric catalysis. The diol was easily converted to the corresponding cyclic sulfate **13**.

As is illustrated in Scheme 2, the requisite 3-carbon allylic carbonate “acceptor” functionality for the carbocyclization could be installed via cyclic sulfate opening with a lithiated propargyl ether. Lindlar semi-hydrogenation and unveiling of the masked terminal olefin, was followed by selective carbonylation of the primary alcohol. The propiolate moiety then enters with Mitsunobu inversion at the HKR-derived stereocenter.

The title bromorhodiation/carbocyclization was carried out on **18a**,² crafting both the *Z*-configured C-Br bond and the ring-forming C-C bond, thereby setting in place the requisite cis-1,3-ring fusion in **19a**. Moreover, a detailed study (50 mg scale) showed that yields could be increased to >90%, with 5 mol % catalyst, by reducing temperature and increasing reaction time (Supporting Information). Note that this formal halometalation/carbocyclization bears some resemblance, particularly in the product structure, to Rh(I)-mediated carbocyclizations reported by Zhang, that involve formal Alderene alkyne/allyl C-H cycloisomerization¹⁶ or alkyne/allylic C-Cl condensation, with an accompanying halide shift.¹⁷ The vinyl halide geometry obtained here is opposite that found in the Zhang chemistry, and both the Rh catalyst (Rh(II)-perfluorocarboxylate/LiBr) and educts (allylic carbonates) employed here also differ.

Subsequent RCM (Grubbs II catalyst)¹⁸ closes the bicyclo[4.3.1]decenyl linearifolin core. The 3D-structure of the core was solved by x-ray crystallography which also served to confirm absolute stereochemistry (Scheme 3). The antipodal series follows from the (*R*)-epoxide obtained in the initial HKR of 5-benzyloxy-pentene oxide mediated by Co(III)-**4a**-OAc (Scheme 1). The sequence mirrors that described for entry into the linearifolin core with the exception that epoxide **9b**, rather than a cyclic sulfate is opened by the lithiated

propargyl ether, a reaction found to proceed optimally in the presence of F_3B-OEt_2 (Scheme 4). Here too, x-ray crystallography established 3D structure and absolute stereochemistry.

In the course of this investigation, it was also discovered that one could gain access to ring contracted cores by RCM modification. Olefin isomerization is known to occasionally accompany metathesis, presumably via the intermediacy of Ru-H species, as studied by Schmidt,¹⁹ Grubbs²⁰ and Snapper.²¹ This serves as an added benefit of this synthetic route, with the Grubbs I catalyst²² giving ring contraction, and thereby access to the oxabicyclo[3.3.1]nonyl core in zinagrandinolide²³ and xerophilusin R²⁴ (Scheme 5), both antineoplastic natural products.^{23–24} Future studies will be directed at the further exploration of this promising β -pinene-based salen scaffold in asymmetric catalysis, and this versatile halocarbocyclization transformation, and at the deployment of these NP cores in chemical biology.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The NSF (CHE-0911732) is acknowledged for support. Xiang Fei and Robert A. Swyka are thanked for assistance. Douglas Powell (U. of Oklahoma) is acknowledged for X-ray structures. Thanks to the NIH (SIG-1-510-RR-06307)/NSF (CHE-0091975, MRI-0079750) (NMR,) & NIH (RR016544) (facilities).

References

1. (a) Berkowitz DB, Shen W, Maiti G. *Tetrahedron: Asymmetry*. 2004; 15:2845–2851. (b) Berkowitz DB, Maiti G. *Org Lett*. 2004; 6:2661–2664. [PubMed: 15281738] (c) Berkowitz DB, Bose M, Choi S. *Angew Chem, Int Ed*. 2002; 41:1603–1607.
2. Friest JA, Broussy S, Chung WJ, Berkowitz DB. *Angew Chem, Int Ed*. 2011; 50:8895–8899.
3. (a) Dey S, Powell DR, Hu C, Berkowitz DB. *Angew Chem, Int Ed*. 2007; 46:7010–7014. (b) Dey S, Karukurichi KR, Shen W, Berkowitz DB. *J Am Chem Soc*. 2005; 127:8610–8611. [PubMed: 15954763]
4. (a) Merfort I. *Curr Drug Targets*. 2011; 12:1560–1573. [PubMed: 21561425] (b) Wagner S, Hofmann A, Siedle B, Terfloth L, Merfort I, Gasteiger J. *J Med Chem*. 2006; 49:2241–2252. [PubMed: 16570920]
5. (a) Kalidindi S, Jeong Won B, Schall A, Bandichhor R, Nosse B, Reiser O. *Angew Chem Int Ed*. 2007; 46:6361–6363. (b) Edwards MG, Kenworthy MN, Kitson RRA, Scott MS, Taylor RJK. *Angew Chem Int Ed*. 2008; 47:1935–1937. (c) Kummer DA, Brenneman JB, Martin SF. *Org Lett*. 2005; 7:4621–4623. [PubMed: 16209494] (d) Hodgson DM, Talbot EPA, Clark BP. *Org Lett*. 2011; 13:5751–5753. [PubMed: 21981361]
6. Nosse B, Chhor RB, Jeong WB, Boehm C, Reiser O. *Org Lett*. 2003; 5:941–944. [PubMed: 12633111]
7. (a) Han C, Barrios FJ, Riofski MV, Colby DA. *J Org Chem*. 2009; 74:7176–7179. [PubMed: 19697954] (b) Moiese J, Arseniyadis S, Cossy J. *Org Lett*. 2007; 9:1695–1698. [PubMed: 17407299]
8. (a) Riofski MV, John JP, Zheng MM, Kirshner J, Colby DA. *J Org Chem*. 2011; 76:3676–3683. [PubMed: 21491928] For an elegant Pauson-Khand entry into the related guaianolides, that introduces the α -methylene lactone at an early stage, see: (b) Grillet F, Huang C, Brummond KM. *Org Lett*. 2011; 13:6304–6307. [PubMed: 22070869]
9. (a) Basu S, Ellinger B, Rizzo S, Deraeve C, Schurmann M, Preut H, Arndt HD, Waldmann H. *Proc Natl Acad Sci U S A*. 2011; 108:6805–6810. [PubMed: 21415367] (b) Dekker FJ, Koch MA, Waldmann H. *Current Opinion in Chemical Biology*. 2005; 9:232–239. [PubMed: 15939324]
10. Zdero C, Bohlmann F, Boldt PE. *Phytochemistry*. 1991; 30:1585–1590.

11. Pettit GR, Herald CL, Gust D, Herald DL, Vanell LD. *J Org Chem.* 1978; 43:1092–5.
12. Van Calsteren MR, Jankowski CK, Reyes-Chilpa R, Jimenez-Estrada M, Campos MG, Zarazua-Lozada A, Oropeza M, Lesage D. *Can J Chem.* 2008; 86:1077–1084.
13. (a) Fang YQ, Jacobsen EN. *J Am Chem Soc.* 2008; 130:5660–5661. [PubMed: 18393504] (b) Nielsen LPC, Stevenson CP, Blackmond DG, Jacobsen EN. *J Am Chem Soc.* 2004; 126:1360–1362. [PubMed: 14759192] (c) Schaus SE, Brandes BD, Larrow JF, Tokunaga M, Hansen KB, Gould AE, Furrow ME, Jacobsen EN. *J Am Chem Soc.* 2002; 124:1307–1315. [PubMed: 11841300]
14. (a) Zhang Q, Lu X, Han X. *J Org Chem.* 2001; 66:7676–7684. [PubMed: 11701020] (b) Zhu G, Lu X. *Organometallics.* 1995; 14:4899–4904.
15. Broussy S, Cheloha RW, Berkowitz DB. *Org Lett.* 2009; 11:305–308. [PubMed: 19128188]
16. (a) Ma S, Lu L, Zhang J. *J Am Chem Soc.* 2004; 126:9645–9660. [PubMed: 15291568] (b) Lei A, Waldkirch JP, He M, Zhang X. *Angew Chem, Int Ed.* 2002; 41:4526–4529.
17. (a) Tong X, Li D, Zhang Z, Zhang X. *J Am Chem Soc.* 2004; 126:7601–7607. [PubMed: 15198608] (b) Tong X, Zhang Z, Zhang X. *J Am Chem Soc.* 2003; 125:6370–6371. [PubMed: 12785768]
18. Scholl M, Ding S, Lee CW, Grubbs RH. *Org Lett.* 1999; 1:953–956. [PubMed: 10823227]
19. Schmidt B. *Eur J Org Chem.* 2004:1865–1880.
20. Hong SH, Sanders DP, Lee CW, Grubbs RH. *J Am Chem Soc.* 2005; 127:17160–17161. [PubMed: 16332044]
21. (a) Finnegan D, Seigal BA, Snapper ML. *Org Lett.* 2006; 8:2603–2606. [PubMed: 16737324] (b) Sutton AE, Seigal BA, Finnegan DF, Snapper ML. *J Am Chem Soc.* 2002; 124:13390–13391. [PubMed: 12418884]
22. Schwab P, Grubbs RH, Ziller JW. *J Am Chem Soc.* 1996; 118:100–110.
23. Bashyal BP, McLaughlin SP, Gunatilaka AAL. *J Nat Prod.* 2006; 69:1820–1822. [PubMed: 17190470]
24. Niu XM, Li SH, Na Z, Lin ZW, Sun HD. *Helv Chim Acta.* 2004; 87:1951–1957.

Figure 1.
Targeted Oxabicyclo[4.3.1]decyl SQL Cores

Figure 2.
Retrosynthetic Analysis

Figure 3.

ISES Readout on Salen-Set/New Reporting Enzymes

ISES screens for sense (+ *S*; – *R*) and magnitude of enantioference for Co(III)-salen-mediated HKR with hexene oxide (purple) and propylene oxide (green) and ^{3a} 1,2-Diamines: **4** (β-pinene-derived); **5** (L-β-naphthyl-Ala-derived); **6** (L-Phe-derived); **7** (L-phenyl-Gly-derived). Hydroxybenzaldehydes: **a** (α-hydroxy-β-naphthaldehyde); **b** (3,5-diiodosalicylaldehyde); **c** (3-*t*-Bu-salicylaldehyde); **d** (3,5-di-*t*-Bu-salicylaldehyde). Note: For entries **4c**, **5b,c**, **6a–d** & **7a–d** new reporting enzymes (KRED (Ketoreductase) 107 – *S*-selective; KRED 119 *R*-selective) for the HKR of hexene oxide were employed.

Scheme 1.
HKR (salen **4a**) Provides both SQL Building Blocks

Scheme 2.
Convergent Assembly of the Halometalation/Carbocyclization Substrate

Scheme 3.
Halometalation/Carbocyclization-RCM Sequence into the Linearifolin Core

Scheme 4.
(R)-Epoxide Leads into the Zaluzanin A Core

Scheme 5.

Isomerization-RCM: Oxabicyclo[3.3.1]nonyl Cores of Zinagrandinolide/Xerophilusin R

Table 1HKR of AcO-Co(III)-**4a** Across Potential Synthons

epoxide	conv	% ee; E-value (epoxide)	% ee; E-Value (diol)
8	44%	52% (12)	80% (17)
9	47%	92% (182)	97% (183)
10	51%	93% (60)	90% (66)
11	44%	75% (97)	96%

Conditions: 1.3 mmol epoxide; 0.67 mmol H₂O in 100 μ L THF, with 2.5 mol % Co(III)-salen derived from **4a**. Conversion estimated by NMR and ee by HPLC-chiral stationary phase (Supporting Information).